Arecor Therapeutics PLC Arecor on Investor Meet Company Platform

TIDMAREC

Arecor Therapeutics PLC

21 April 2023

Arecor Therapeutics plc

("Arecor" or the "Group")

Arecor to present on Investor Meet Company Platform

Cambridge, UK, 21 April 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Sarah Howell, Chief Executive Officer and Susan Lowther, Chief Financial Officer will be providing a live presentation relating to the Group's recently announced results for the year ended 31 December 2022 via the Investor Meet Company platform, on Wednesday 26 April 2023 at 14.00pm BST.

The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event through the Investor Meet Company dashboard until 9am BST on Tuesday 25 April, or at any time during the live presentation.

To sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit:

https://www.investormeetcompany.com/arecor-therapeutics-plc/register-investor .

Investors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                  www.arecor.com 
 Dr Sarah Howell, Chief Executive         Tel: [phone] 
  Officer                                  Email: [e-mail] 
 
 Susan Lowther, Chief Financial Officer   Tel: [phone] 
                                           Email: [e-mail] 
 
 Mo Noonan, Communications                Tel: [phone] 
                                           Email: [e-mail] 
 
 Panmure Gordon (UK) Limited (NOMAD 
  and Broker) 
 Freddy Crossley, Emma Earl (Corporate    Tel: [phone] 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Lindsey      Tel: [phone] 
  Neville                                  Email: [e-mail] 
 
 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM) , we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat (TM) platform is supported by an extensive patent portfolio . For further details please see our website, www.arecor.com

-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAIMMLTMTMTBFJ

(END) Dow Jones Newswires

April 21, 2023 02:00 ET (06:00 GMT)